Evogene Ltd. (EVGN) Stock Forecast
EVGN analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $2.15 average of analyst targets
- Upside to target
- +451.3% from the latest close
- Next earnings
- November 19, 2026 EPS estimate $-0.19
- 52-week range
- $0.38 – $1.31
EVGN analyst ratings
1 analystsNumber of analysts at each rating.
EVGN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
EVGN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.19 | −$0.19 | −$0.19 | −$0.46 | +59.1% | 1 |
| Current fiscal year (2026) | −$1.10 | −$1.10 | −$1.10 | −$1.63 | +32.6% | 1 |
| Next fiscal year (2027) | −$0.60 | −$0.60 | −$0.60 | −$1.10 | +45.5% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
EVGN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $365,000 | $365,000 | $365,000 | +17.0% | 1 |
| Current fiscal year (2026) | $1.4M | $1.4M | $1.4M | −62.7% | 1 |
| Next fiscal year (2027) | $2.6M | $2.6M | $2.6M | +81.1% | 1 |
EVGN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
EVGN revenue: reported and forecast
EVGN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.27 | −$0.27 | −$0.27 | −$0.27 | −$0.19 | −29.6% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.70 | −$1.70 | −$1.70 | −$1.70 | −$1.10 | −35.3% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.80 | −$0.80 | −$0.80 | −$0.80 | −$0.60 | −25.0% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
EVGN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; EVGN beat in 8 of 12.
What analysts expect from EVGN
1 analysts cover Evogene; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $2.15, 451.3% above the latest close of $0.39. Analysts expect earnings of −$1.10 per share for 2026, +32.6% from a year earlier. For 2027 the average estimate is −$0.60 per share on revenue of $2.6 million. Evogene beat the EPS estimate in 8 of the last 12 quarters.
Related: EVGN income statement, EVGN key metrics, EVGN chart. See the EVGN stock overview for the latest quote and news.
EVGN forecast FAQ
What is Evogene's price target?
The average analyst price target for Evogene is $2.15, 451.3% above the latest close of $0.39.
Is Evogene a buy, hold or sell?
Of 1 analysts covering Evogene, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Evogene's EPS forecast?
Analysts forecast −$1.10 per share for 2026 (range −$1.10 to −$1.10); for 2027 the estimate is −$0.60.
What is Evogene's revenue forecast?
The average revenue estimate for 2026 is $1.4 million, growth of −62.7%; for 2027 it is $2.6 million.
When does Evogene report earnings?
Evogene is expected to report results for the quarter ending September 30, 2026 on November 19, 2026 before the market opens; the EPS estimate is $-0.19.
Does Evogene usually beat earnings estimates?
Evogene reported EPS at or above the analyst estimate in 8 of the last 12 quarters.